纤溶酶原激活物抑制剂-1与动脉粥样硬化

[1] Impaired fibrinolysis and the risk for coronary heart disease. H Roger L,Desire C. Circulation . 1996

[2] Antifibrinolytic properties of the vascular wall. Gunter C,Peter H,Christoph K,et al. Arteriosclerosis Thrombosis and Vascular Biology . 1997

[3] Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1(PAI1) gene by proinsulin in vivo. Nordt TK,Sawa H,Fujii S,et al. Journal of Molecular and Cellular Cardiology . 1998

[4] Comparative analysis of plasminogen activator inhibitor- 1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Teresa P,Martin S,Chang- Xun Li,et al. Cardiovascular Research . 1997

[5] Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Linda AR,Nuala AB,Paul AJB,et al. Arteriosclerosis and Thrombosis . 1996

[6] Fibronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Pascale D,Huguette L,Catherine M,et al. Arteriosclerosis Thrombosis and Vascular Biology . 1998

[7] Vascular endothelial growth factor B (VEGF - B) binds to VEGF receptor - 1 and regulates plasminogen activator activity in endothelial cells. Birgitta OF,Eija K,Michaels,et al. Proceedings of the National Academy of Sciences of the United States of America . 1998

[8] Genotype- specific transcriptional regulation of PAI - 1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Xin Nong Li,Hernan EG,Raymond LB,et al. Arteriosclerosis and Thrombosis . 1997

[9] Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Nasr A,Breckwoldt M. Gynecological Endocrinology . 1998

[10] Atherosclerosis [P].

[1] Impaired fibrinolysis and the risk for coronary heart disease. H Roger L,Desire C. Circulation . 1996

[2] Antifibrinolytic properties of the vascular wall. Gunter C,Peter H,Christoph K,et al. Arteriosclerosis Thrombosis and Vascular Biology . 1997

[3] Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1(PAI1) gene by proinsulin in vivo. Nordt TK,Sawa H,Fujii S,et al. Journal of Molecular and Cellular Cardiology . 1998

[4] Comparative analysis of plasminogen activator inhibitor- 1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Teresa P,Martin S,Chang- Xun Li,et al. Cardiovascular Research . 1997

[5] Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Linda AR,Nuala AB,Paul AJB,et al. Arteriosclerosis and Thrombosis . 1996

[6] Fibronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Pascale D,Huguette L,Catherine M,et al. Arteriosclerosis Thrombosis and Vascular Biology . 1998

[7] Vascular endothelial growth factor B (VEGF - B) binds to VEGF receptor - 1 and regulates plasminogen activator activity in endothelial cells. Birgitta OF,Eija K,Michaels,et al. Proceedings of the National Academy of Sciences of the United States of America . 1998

[8] Genotype- specific transcriptional regulation of PAI - 1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Xin Nong Li,Hernan EG,Raymond LB,et al. Arteriosclerosis and Thrombosis . 1997

[9] Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Nasr A,Breckwoldt M. Gynecological Endocrinology . 1998

[10] Atherosclerosis [P].